ClinicalTrials.gg
CompletedNCT04046809Updated Apr 29, 2022

Study of Neurotidine® Intake on Life Quality of Patients With Glaucoma

An interventional study of Food for special medical purposes: Neurotidine® and Placebo in Glaucoma, sponsored by Omikron Italia S.r.l.. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-29.

Sponsored by Omikron Italia S.r.l. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Feb 2019, registered Jul 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Glaucoma with a site in Italy — 7 open to participants now, 8 under way, 1 of them phase 3. Glaucoma · Italy.

Enrollment
8th of 39
155 · median 64
Started
2019
with 1 other
No phase
17 of 53
1 open now
Registered
34th of 53
by date

Among the 53 studies in Glaucoma with a site in Italy, this one is the 8th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2019, is one of 17 with no phase, and was the 34th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

7 of the 53 studies in Glaucoma with a site in Italy are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Glaucoma with a site in Italy, or all of them as a file.
02

Study summary

The purpose for the study consists in the assessment of the role of Neurotidine® (citicoline oral solution) on the dopaminergic pathway and particularly its potential implications on psychophysical performance and quality of life. Other objectives are the assessment of the tolerability and safety of Neurotidine®.

Read the detailed description

Primary open angle glaucoma is a chronic progressive neurodegenerative disease and the only proven effective therapy involves reduction of intraocular pressure (IOP). Although treatment effect is quite large, a significant proportion of patients show disease progression with apparently controlled IOP. Given the similarities with other neurodegenerative diseases - particularly in the mechanisms of cell death -neuroprotective treatments have been tried also in glaucoma. Interesting results from experimental studies and weak evidence from human glaucoma trials have been published in recent years. Citicoline is one of the promising molecules with a putative neuroprotective action and has been tried on patients with a number of neurodegenerative diseases with encouraging results. Pilot studies on glaucomatous patients showed a possible effect of citicoline in reducing progression of visual field changes, though these findings need to be confirmed by larger randomized clinical trials.

The aim of this randomized, double-masked, placebo-controlled, cross-over study is to test whether the intake of Neurotidine® (citicoline free acid in oral solution) can be associated with an improvement of quality of life in patients with glaucoma.

03

Conditions studied

  • Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all the following criteria to be eligible for the study:

  • Signed written .
  • Age ≥ 18 years.
  • Patients with bilateral open-angle glaucoma (OAG). PEX and pigmentary glaucoma will be included.
  • Controlled IOP
  • Patients with moderate damage in the better eye, with mean deviation from normal value (MD) ranging from -6 to -12 dB in the 6 months prior to enrollment. At the screening assessment, MD must range from -5 to -13 dB.

Glaucoma definition will be based on visual field (VF) damage (24-2, SITA standard strategy) corresponding to glaucomatous changes at the optic nerve head. Values of IOP will not be an inclusion criterion, though a "controlled IOP" based on the clinician's judgement will be required.

Exclusion criteria

Exclusion Criteria:

Patients must meet none of the following criteria to be eligible for the study:

  • Single-eyed patients (visual acuity \<0.1 in one eye).
  • Patients without the psychophysical requirements to adequately participate and complete the trial.
  • Patients with chronic angle-closure glaucoma (CACG) or other types of glaucoma.
  • Patients with other ocular comorbidities interfering with the correct assessment of the glaucomatous damage to the VF.
  • Patients who have undergone surgery within 6 months.
  • Patients taking other potential neuroprotectors, including topical, competing with Neurotidine®.
  • Patients with Parkinson's disease, dementia or a diagnosis of stroke in the last 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Study Treatment

    500 ml oral solution containing citicoline free acid 50 mg/ml.

    Other: Food for special medical purposes: Neurotidine®

  • Placebo comparator
    Placebo

    500 ml oral solution indistinguishable from active product in appearance and taste

    Other: Placebo

Interventions

  • OtherFood for special medical purposes: Neurotidine®

    Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months). Administration at a dosage of 10 ml in the morning.

  • OtherPlacebo

    Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months). Administration at a dosage of 10 ml in the morning.

06

What researchers measure

Primary outcomes

  1. The mean change of "intra-patient" global score of the Visual Functioning Questionnaire 25 (VFQ-25) after Neurotidine® vs placebo.

    Primary outcome is based on the global score of the VFQ-25 questionnaire. Specifically, the VFQ-25 consists of a base set of 25 vision targeted questions. The global score derives from the summary of the scores deriving from each question. The total score has a minimum value "0" considered as the worst visual functionality, and the maximum value "100" considered as the better visual functionality.

    Time frame: At 6 months compared to baseline

Secondary outcomes

  1. The change of other scores of the questionnaire: Visual Functioning Questionnaire 25 (VFQ-25).

    Other score utilized in the study: general health, general vision, near and far activities, social, mental, role difficulties, etc.

    Time frame: Up to 9 months compared to baseline

  2. The change of other scores of the questionnaire: Short Form Health Survey - 36 items (SF-36).

    Other score utilized in the study: general health, general vision, near and far activities, social, mental, role difficulties, etc.

    Time frame: Up to 9 months compared to baseline

  3. The safety and tolerability of Neurotidine®.

    The safety and tolerability of Neurotidine® will be detected on the basis of possible adverse events. In particular, they will be documented in the CRF. Possible adverse events will be communicated directly by the patient and/or detected by the Investigator during the medical examination.

    Time frame: Up to 9 months compared to baseline

07

Study locations

5 sites
  • University Hospitals Leuven
    Leuven, Belgium
  • Aristotle University of Thessaloniki AHEPA Hospital Thessaloniki
    Thessaloniki, Greece
  • Presidio Ospedale San Paolo
    Milano, MI 20142, Italy
  • Fondazione PTV Policlinico Tor Vergata
    Roma, 00133, Italy
  • CTIG - Teknon
    Barcelona, Spain
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Dec 2021, 33 months.

Of 58 industry-sponsored interventional studies with no phase under Glaucoma, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's 33 months is above that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2019
First posted
Aug 6, 2019
StartActual
Feb 13, 2019
Primary completionActual
Dec 7, 2021
CompletionActual
Jan 24, 2022
Last update
Apr 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04046809
Lead sponsor
Omikron Italia S.r.l.
Responsible party
Sponsor
First posted
Aug 6, 2019
Start date
Feb 13, 2019
Primary completion
Dec 7, 2021
Completion
Jan 24, 2022
Last update
Apr 29, 2022

Study contacts

Luca Rossetti, Prof.
principal investigator · Presidio Ospedale San Paolo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion